Protara announces updated interim data from Phase 2 ADVANCED-2 trial

Protara Therapeutics (TARA) announced updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS non-muscle invasive bladder cancer, NMBIC. These results in Bacillus Calmette-Guerin-Naive NMIBC patients will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology in Phoenix, Arizona. Updated Interim Results: The CR rate at any time was 72%; The CR rate was 69% at six months and 50% at 12 months; Among initial responders, 88% maintained their response through six months and 100% through 12 months; Re-induction therapy successfully salvaged most initial non-responders, resulting in high conversion rates and durable responses: 80% of re-induced patients converted to a CR at 6 months, and 100% of those responders maintained their CR at 12 months. CEO Jesse Shefferman said, “”We remain on track to provide an update on the registrational BCG-Unresponsive patient cohort in the ADVANCED-2 trial in the first quarter of 2026 and expect to complete enrollment of this cohort in the second half of 2026.”